Blake Henderson

🦠 I am worried about a bias I increasingly see in parts of the Long COVID discussion. And I say this with respect, because patients are suffering and many researchers are doing important work. But there is a kind of “pathogen tunnel vision” that can happen when one virus becomes the center of everything. The pattern is: “This disease is completely new.” “This virus is the only one that persists.” “This virus is the only one that causes immune exhaustion.” “This virus is the only one that causes reactivations.” “This virus is the only one that causes autoimmunity.” “This virus is the only one that causes dysautonomia.” “This virus is the only one that causes acquired immune dysfunction.” But biology is usually not that exclusive. SARS-CoV-2 is important. Long COVID is real. Viral persistence, immune activation, herpesvirus reactivation, autoimmunity, dysautonomia, endothelial dysfunction and coagulation abnormalities may all be relevant in subsets of patients. But SARS-CoV-2 is not the only pathogen capable of pushing the immune system into chronic dysfunction. EBV has been associated with multiple sclerosis, lupus, rheumatoid arthritis, Sjögren’s and ME/CFS. Enteroviruses have been discussed for decades in ME/CFS. Borrelia can be followed by persistent symptoms and dysautonomia. Other intracellular or tissue-resident pathogens can also persist, evade immunity, maintain antigenic stimulation and trigger chronic inflammatory states. So the more useful question is not: “Is SARS-CoV-2 unique?” The more useful question is: “What mechanisms does SARS-CoV-2 share with other persistent or post-infectious pathogens, and what mechanisms are specific to it?” Because if we pretend every Long COVID mechanism is completely new, we risk ignoring decades of work from ME/CFS, post-EBV disease, enteroviruses, Lyme, herpesviruses and other post-infectious syndromes. And if we pretend SARS-CoV-2 explains every chronic immune disease now, we also risk erasing patients who developed similar syndromes before 2020. The pandemic made the problem visible at massive scale. That matters. Millions of people were infected in a short period of time, and reinfections keep adding new cases. So Long COVID may be larger and more visible than other post-infectious conditions. But larger does not mean biologically isolated. Many pathogens can converge on similar pathways: persistent antigenic stimulation → chronic immune activation → T-cell dysfunction or exhaustion-like states → herpesvirus reactivation → mast cell activation → endothelial dysfunction → dysautonomia → loss of tolerance → autoimmunity in susceptible hosts. The host matters too. Genetics, HLA background, barrier integrity, immune regulation and previous infections can shape whether someone clears a pathogen and recovers, or develops chronic disease. So my concern is not that SARS-CoV-2 is being studied too much. It should be studied much more. My concern is when Long COVID is treated as if it exists outside the rest of immunology. We would move faster if we compared mechanisms across post-infectious diseases instead of building walls between them. Long COVID research can help ME/CFS. ME/CFS research can help Long COVID. EBV research can help both. The same applies to enteroviruses, herpesviruses, Borrelia and other persistent pathogens. The goal should not be to prove that “my pathogen explains everything.” The goal should be to understand why persistent antigens break immune regulation in susceptible people. That is where the real answers may be.